文献速递淋巴瘤

集落刺激因子-1受体(CSF-1R)是滤泡性淋巴瘤的新型预后因素和治疗靶点

The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma.
PubMed 文献 · Leukemia · 2021-03-17

本研究利用滤泡性淋巴瘤(FL)原代样本、滤泡树突状细胞(FDC)共培养及小鼠模型,分析FL-FDC-巨噬细胞三方交互。发现FL-FDC通过分泌CCL2和CSF-1促进单核细胞招募并极化为M2样促肿瘤表型,CSF-1R高表达与3A级、总生存降低和转化风险相关;抑制CSF-1R可减少M2并协同利妥昔单抗抗肿瘤。

要点

  • FL-FDC通过CCL2/CSF-1促进单核细胞向M2样巨噬细胞极化。
  • CSF-1R高表达与FL 3A级、总生存降低及转化风险相关。
  • CSF-1R抑制剂pexidartinib可重极化巨噬细胞并协同利妥昔单抗。

核心结论

  • CSF-1R是FL的相关预后因素和与抗CD20免疫治疗协同的新型治疗靶点。

研究设计与样本

  • 使用FL原代样本(n=19)与HK滤泡树突状细胞共培养,结合小鼠共异种移植模型分析FL-FDC-巨噬细胞三方交互。

主要发现

  • FL-FDC共培养和小鼠共异种移植显示FL-FDC交互促进肿瘤生长。
  • FL-FDC通过分泌CCL2和CSF-1促进单核细胞招募、分化和向M2样促肿瘤表型极化。
  • FL-M2共培养显示血管生成、播散和免疫抑制增强。
  • 3A级FL患者血清CSF-1显著升高,FL活检中CSF-1R高表达与3A级、总生存降低和转化风险相关。
  • Pexidartinib抑制CSF-1R优先影响M2巨噬细胞活力和极化程序,体内减少M2并促M1重极化,与利妥昔单抗协同抗肿瘤。

临床怎么用

  • CSF-1R表达或可辅助FL预后分层,尤其关注3A级和转化风险。
  • CSF-1R抑制剂联合抗CD20单抗可能成为FL治疗新策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Microenvironment contributes to follicular lymphoma (FL) pathogenesis and impacts survival with macrophages playing a controversial role. In the present study, using FL primary samples and HK follicular dendritic cells (FDC) to mimic the germinal center, together with mouse models, we have analyzed the three-way crosstalk of FL-FDC-macrophages and derived therapeutic opportunities. Ex vivo primary FL-FDC co-cultures (n = 19) and in vivo mouse co-xenografts demonstrated that FL-FDC crosstalk favors tumor growth and, via the secretion of CCL2 and CSF-1, promotes monocyte recruitment, differentiation, and polarization towards an M2-like protumoral phenotype. Moreover, FL-M2 co-cultures displayed enhanced angiogenesis, dissemination, and immunosuppression. Analysis of the CSF-1/CSF-1R pathway uncovered that CSF-1 was significantly higher in serum from grade 3A FL patients, and that high CSF-1R expression in FL biopsies correlated with grade 3A, reduced overall survival and risk of transformation. Furthermore, CSF-1R inhibition with pexidartinib (PLX3397) preferentially affected M2-macrophage viability and polarization program disrupting FL-M2 positive crosstalk. In vivo CSF1-R inhibition caused M2 reduction and repolarization towards M1 macrophages and antitumor effect cooperating with anti-CD20 rituximab. In summary, these results support the role of macrophages in FL pathogenesis and indicate that CSF-1R may be a relevant prognostic factor and a novel therapeutic target cooperating with anti-CD20 immunotherapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Valero JG, Matas-Céspedes A, Arenas F, et al. The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia. 2021. PMID: 33731849. doi:10.1038/s41375-021-01201-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。